SFN preferentially eliminates breast CSCs by suppressing or downregulating NF-κB p65 subunit translocation, downstream transcriptional activity, and p52 proteins. SFN reverses ALDH+ cell enrichment induced by taxane and consequently reduces the volume of resultant primary and secondary mammospheres formed. Combining SFN and taxanes increases the suppression of secondary tumor formation. The ddition of SFN to conventional breast cancer treatments can prevent the expansion of and facilitate the elimination of breast CSCs. The gene discussed is LDHA; the disease is breast cancer.